Jun. 19 at 11:06 PM
$GANX Favorable FDA tailwinds opening door to fast track accelerated approvals. FDA motivated to support safe and efficacious drugs targeting neurodegenerative dseases. No standard of care.
M&A heating up as pharma seeks to replace
$150B in revenue soon to be extinguished due to patent cliff. Neuroscience is the sweetspot.
$500M+/- is pocket change for pharma.
Many of us, analysts too, believe GT-02287 could be a multi billion $ drug and it is feasible.
That said, I will not be surprised, as Gene has hinted, if we see a new name on the door as early as year end. I continue to believe the true value of the drug and pipeline will be unlocked inside the scale of a large pharma, just as I predicted with Teplizumab and Provention Bio.
The next 6 months are a perfect storm for this company and with the right data, I can't imagine pharma not striking.
My target price is slightly lower than some here, but if I'm remotely close to right, shareholders will still do very well. DYDD
